论文部分内容阅读
目的:通过对胃癌前病变 (PLGC) 大鼠炎症因子等相关指标的检测, 阐释五丹胃福颗粒对胃癌前病变大鼠的防治作用.方法:SD大鼠40只, 采用改良MNNG+复合法制备PLGC模型, 随机分为五丹胃福颗粒高、低剂量组, 西药 (叶酸) 组及模型组, 每组10只, 连续灌胃给药12周, 另取10只正常大鼠设为空白组, 灌胃0.9％氯化钠注射液.采用ELISA法检测各组大鼠血清COX-2、IL-1β、TNF-α、NF-κB水平.结果:与空白组比较, 模型组各指标水平均升高, 差异均有统计学意义 (P<0.01);与模型组比较, 各治疗组指标水平均降低, 差异均有统计学意义 (P<0.01);五丹胃福颗粒高、低剂量组与西药组COX-2、NF-κB水平差异有统计学意义 (P<0.05);五丹胃福颗粒低剂量组与西药组TNF-α、IL-1β水平差异有统计学意义 (P<0.01) .结论:五丹胃福颗粒通过抑制PLGC大鼠炎症因子表达, 从而影响PLGC的发生发展, 并且与叶酸的治疗作用相当.“,”Objective: To investigate the preventive and therapeutic effects of Wudan Weifu granules in rats with precancerous lesion of gastric cancer (PLGC) by measuring related indices including inflammatory factors. Methods: A total of40 Sprague-Dawley rats were treated with the modified MNNG + compound method to establish a model of PLGC, and then they were randomly divided into high-and low-dose Wudan Weifu granule groups, Western medicine (folic acid) group, and model group, with 10 rats in each group. The drugs were given by gavage for 12 consecutive weeks. Another 10 normal rats were selected as blank group and were given 0. 9％ sodium chloride injection by gavage. ELISA was used to measure the serum levels of cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and nuclear factor-kappa B (NF-κB). Results: Compared with the blank group, the model group had significant increases in the levels of the above indices (P < 0. 01); compared with the model group, each treatment group had significant reductions in the levels of these indices (P < 0. 01). There were significant differences in the levels of COX-2 and NF-κB between the high-and low-dose Wudan Weifu granule groups and the Western medicine group (P < 0. 05), and there were significant differences in the levels of TNF-α and IL-1β between the low-dose Wudan Weifu granule group and the Western medicine group (P < 0. 01). Conclusion: Wudan Weifu granules can influence the development and progression of PLGC by inhibiting the expression of inflammatory factors in rats with PLGC and has a similar therapeutic effect as folic acid.